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Introduction 
Pancreatic Cancer (PC) is the third leading cause of cancer mortality in the West, 
after recently overtaking breast cancer.1 There has been little improvement in the 
overall outcomes for PC in the last 50 years. Recently there have been small 
incremental improvements in overall survival in the metastatic setting based on the 
PRODIGE-4 / ACCORD-11 and MPACT clinical trials2,3; and in the adjuvant setting 
with Gemcitabine-Capecitabine and FOLFIRINOX combinations4,5. Neoadjuvant 
therapy is gaining popularity in the borderline resectable and locally advanced 
settings with some exceptional responses leading to long-term survival in undefined 
subgroups.6-9 The incremental improvements are likely due to the effects of these 
small undefined subgroups of responders with the majority of patients gaining 
minimal or no benefit from systemic chemotherapy such as Gemcitabine 
combinations and the FOLFIRINOX regimen.10,11 Therefore, a selection biomarker 
driven precision oncology approach is urgently needed in PC.  
In this editorial we will summarise some of the effort of translating clinically relevant 
genome discovery into the real world and highlight a few candidate therapeutic 
segments in development. 
 
The mutational landscape of PC 
Recently, there has been a vast expansion in the understanding of the molecular 
pathology in many cancer types including PC. The ‘omics’ revolution is rapidly 
generating large-scale datasets including whole genome and whole transcriptome 
sequencing from a large number of tumours. The Australian Pancreatic Cancer 
Genome Initiative (APGI, (http://www.pancreaticcancer.net.au)) led the contribution 
of 450 PC to the International Cancer Genome Consortium (ICGC, 
(https://icgc.org)),12-14 making significant headway in the understanding of the 
mutational landscape of the disease, as well as clinically relevant molecular 
subtypes. Whole exome sequencing and copy number alteration analyses of 142 
resected PCs reaffirmed the mutational profile originally described in a landmark 
study describing 12 core signalling pathways and gained further insights into the 
molecular pathology of PC.13,15 The most frequent mutations in PC include KRAS, 
TP53, SMAD4 and CDKN2A, all of which do not confer effective therapeutic options 
at present.10,13 Yet, this study from the APGI, revealed therapeutic vulnerabilities in 
the disease, including mutations in genes such as BRCA 1 / 2, PALB2, ARID1A and 
ATM.13 Similar findings have also been described by large scale studies from 
Canada and The Cancer Genome Atlas initiative, resulting in 1000 published 
genomes of PC to date16,17.  However, the frequency of actionable mutations in PC 
remains low and highlights the need to for identify alternative biomarkers of 
therapeutic response beyond point mutation. Waddell et al. performed analysis of the 
first 100 whole genomes sequenced (WGS) from APGI, and revealed mutational 
signatures and structural variation patterns associated with defects in DNA damage 
response (DDR).12 Four patterns of structural variation were identified and can be 
associated with underlying mutational processes. The unstable pattern (over 200 
structural variations evenly distributed throughout the genome) overlaps with high 
COSMIC BRCA point mutational signature and mutations in genes involved in DNA 
maintenance such as BRCA1, BRCA2 and PALB2.12 Up to 24% of patients with PC 
exhibit one or more of these putative biomarkers of DDR deficiency, demonstrating 
the potential responsive subgroup to DNA damaging agents (e.g. platinum) may be 
higher than previously thought.12  
 
Molecular Subtypes of PC 
There has been growing interest in molecular ‘subtyping’ beyond the genome to gain 
insights into the molecular processes driving tumour progression and therapeutic 
response. The APGI performed the first large scale multi-omic analyses in PC, using 
transcriptomes, methylome, mutational data and histopathology from 451 patients 
and identified clinically relevant differential gene programs that cluster tumours into 
unique molecular subtypes.14 The study identified four potentially clinically relevant 
molecular subtypes of PC termed Squamous, Pancreatic Progenitor, Aberrantly 
Differentiated Endocrine Exocrine (ADEX) and Immunogenic. The Immunogenic and 
ADEX subtypes were found to be subclasses of the Pancreatic subtype. The 
Squamous subtype was so-called as it is enriched for gene programs that have 
previously been described in squamous cancers of the head and neck, breast, 
bladder and lung18. It is characterised by epigenetic changes such as 
hypermethylation leading to loss of expression of key genes in endodermal 
differentiation such as HNF1B, GATA6, PDX1 and MNX1.14 This subtype is 
associated with inflammatory pathways, immune evasion and epithelial-to-
mesenchymal transition.14 These molecular features of aggressive disease, in turn, 
are associated with poor survival.14  
In contrast, the pancreatic progenitor subtype described by Bailey et al. is enriched 
for genes involved in pancreatic differentiation.14 The Immunogenic subtype was 
enriched for immune cell infiltrates including cytotoxic CD8+ T Cells, regulatory T 
cells and B cells. However, this also included increased expression of CTLA-4 and 
PD-1 immune checkpoints demonstrating immune-modulation that can potentially be 
targeted by immune checkpoint inhibition.14  
 
Molecular therapeutic targets in PC 
Our increasing understanding of the molecular pathology of PC has revealed 
therapeutic vulnerabilities that extend beyond simple somatic mutations. As 
discussed above, up to a quarter of patients with PC may harbour genomic evidence 
of DDR deficiency. This extends beyond germline mutations in BRCA 1 and 2, which 
is currently the selection biomarker for the vast majority of DDR targeted treatment 
strategies and clinical trials. Using surrogate readouts of DDR deficiency, such as 
mutational signatures and structural variation patterns, would likely benefit more 
patients than just point mutations alone. Platinum based chemotherapy regimens 
have demonstrated benefit in all stages of PC3,19,20, and response is likely to be 
related to homologous recombination deficiency (HRD), a dominant subset of DDR 
deficiency, which occur in 10-20% of patients with PC. Significant responses to 
platinum-based chemotherapy occurs in up to a fifth of patients and improvements in 
overall outcomes is likely to due this subgroup of responders to therapy.10,19 
However, platinum-based regimens can be associated with significant adverse 
effects and even mortality. Thus, it is crucial to identify responsive patient subgroups 
to prevent unnecessary morbidity in patients who do not benefit from platinum. 
Surrogate readouts of HRD can be used as a selection biomarker to identify platinum 
responders. This is one of the key research objectives of PRECISION-Panc, a 
therapeutic development platform that aims to rapidly translate key molecular 
discoveries into a precision oncology approach for PC (please see accompanying 
editorial).  
 
Immunotherapy in PC 
To date, single agent immunotherapy trials in PC have been disappointing. Immune 
checkpoint (PD-1 and CTLA4) inhibitors have failed to show significant benefit in PC. 
The microenvironment of PC varies greatly between tumours, and this is likely due to 
differential immune signalling between subtypes of tumour epithelium and stroma. 
The squamous subtype of PC is enriched for immunosuppressive myeloid cell 
infiltration, with an abundance of neutrophil and macrophage signalling resulting in 
sparse T and B cell infiltration leading to immune invasion. Recent genetically 
engineered mouse model studies demonstrated significant benefits in 
pharmacologically induced myeloid depletion in PC. In an attempt to enhance 
immune checkpoint inhibition, several pre-clinical studies have targeted the 
immunosuppressive myeloid cell infiltration seen in PC. Combining CXCR2 inhibitors 
with a PD-1 checkpoint inhibitor improves survival in mouse models of PC.21 In 
another study CSF1R inhibitors reduce immunosuppressive macrophage infiltration 
and results in an active T cell response.22 Whether these preclinical findings 
translate into patient benefit, or if these are subtype specific phenomena remains to 
be determined in the clinical setting. 
The Immunogenic subtype, on the other hand, is enriched for signalling from CD4+ 
and CD8+ T and B cells.14 This is coupled with upregulation of PD-1 and CTLA-4 
expression. Checkpoint inhibition may benefit this subgroup of patients, whilst is 
unlikely to demonstrate any response in the Squamous group, as single agent. This 
indicates that unselected immunotherapy trials, will result in dilution of any 
therapeutic signals leading to clinical trial failures.  
 
PRIMUS trials: Translating pre-clinical platforms of evidence into the clinic 
In an effort to accelerate therapeutic development, a UK wide PRECISION-Panc 
consortium was established in 2016 (please see accompanying editorial). Within the 
clinical development pillar is the PRIMUS (Pancreatic Cancer Individualised Multi-
arm Umbrella Study) clinical trial platform (Figure 1). It was designed to rapidly 
translate preclinical advances into clinical trials for patients with all stages of PC. 
Clinical trials are traditionally dominated by exclusion criteria, resulting in only around 
5% of PC patients currently entering clinical trials. The molecular heterogeneity of 
PC, and often the prolonged period between translating preclinical advances into 
clinical trials have severely hampered progress in improving outcomes for PC. A 
PRECISION-Panc Therapeutic Testing Board has been established to regularly 
review pre-clinical concepts and assess readiness of the concepts to be developed 
into clinical trial. The Therapeutic Testing Board also meets with the NCRI clinical 
studies group Pancreatic Cancer workstream twice per year to ensure 
complementing and aligning therapeutic development. The trials on the PRIMUS 
platform are designed specifically by the scientific advances described above.  
 
PRIMUS-001 and -002 aims to investigate the efficacy of the platinum containing 
regimen FOLFOX-Abraxane compared with Gemcitabine-Abraxane in all and 
biomarker-enriched patients in the first line metastatic and neoadjuvant setting 
respectively. The initial biomarker being tested is a candidate HRD signature, 
derived from the specific pattern of genomic structural re-arrangements seen in 
known HRD cancers from published and unpublished data sets. This is hypothesised 
to be a biomarker of response to platinum-based therapy. The adaptive design of 
these studies allows the discovery and development of the predictive signatures and 
to inform a future molecularly stratified PHASE III trial design if needed. This strategy 
is an overarching goal of PRECISION-Panc by integrating Discovery, with Pre-
clinical development and Clinical trial testing to allow rapid forward and backward 
translation, thereby accelerating scientific advances into the clinic (see 
accompanying editorial).  
 
The concept of PRECISION-Panc is further demonstrated by the PRIMUS-003 trial 
(NCT02583477) which has recently completed recruitment. Based on the preclinical 
data that CXCR2 inhibition blockade significantly abrogated metastasis, and in 
combination with PD-1 extended survival in a genetically engineered mouse model,21  
a clinical trial was rationally designed to assess clinical efficacy in a Phase 1b signal 
seeking fashion. 
 
The PRIMUS-004 umbrella was designed to offer patients a portfolio of 2nd line 
options, with early phase, signal seeking trial design with clear biomarker-based 
hypotheses using well tolerated targeted agents. It aims to offer patients a range of 
options targeting various disease mechanisms and potentially provide therapies for 
those less fit for further cytotoxic chemotherapy. The first Appendix is investigating if 
the combination of an ATR inhibitor (AZD6738) with the PARP inhibitor Olaparib is 
able to overcome acquired resistance to 1st line platinum treatment. Patients who 
had stable disease or better response to platinum containing regimens are stratified 
by mutations in key genes in the homologous recombination repair (HRR) pathway 
to allow comparison between these groups (HRR mutant vs wild-type).  
 
 
Figure 1: PRIMUS trials currently open or approved on the PRECISION-Panc platform 
Conclusions 
With the growing knowledge base of the molecular pathology of PC, we are 
revealing novel therapeutic opportunities in this recalcitrant disease. Furthermore, it 
highlights that underlying inter-patient molecular heterogeneity may have contributed 
to the significant failure rate associated with unselected clinical trials in PC. The 
generation and translation of clinically relevant and robust pre-clinical platforms of 
evidence into well designed clinical trials with parallel molecular profiling of patients’ 
tumours, will ideally lead to improvements in overall survival for this devastating 
disease.  
 
 
 
 
Adaptive phase II study:
FOLFOX-A (FOLFOX + nab-paclitaxel) versus Gem-Abraxane (nab-paclitaxel + gemcitabine) 
In patients with metastatic pancreatic cancer, with integrated biomarker evaluation
An umbrella phase II study:
Examining two regimens (FOLFOX-A and AG) in resectable / borderline 
resectable pancreatic cancer, focusing on biomarker and liquid biopsy development
A phase Ib and II open-label, multi-centre study of CXCR2inh + Check point inhibitor 
evaluated in patients with metastatic pancreatic cancer
Metastatic
An Umbrella phase II study:
Testing combinations that target DNA Damage Repair deficiency and replication stress in 
molecularly selected patients with metastatic pancreatic cancer 
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